Jonathan Yen-Wen Yu Sells 18,612 Shares of Disc Medicine (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON) COO Jonathan Yen-Wen Yu sold 18,612 shares of the company’s stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $69.19, for a total transaction of $1,287,764.28. Following the completion of the sale, the chief operating officer owned 54,324 shares in the company, valued at approximately $3,758,677.56. This trade represents a 25.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Disc Medicine Stock Up 1.0%

Shares of IRON stock traded up $0.73 during trading hours on Thursday, hitting $70.94. 1,562,335 shares of the company’s stock traded hands, compared to its average volume of 584,908. The company has a quick ratio of 24.00, a current ratio of 24.00 and a debt-to-equity ratio of 0.04. The stock’s fifty day simple moving average is $68.44 and its two-hundred day simple moving average is $71.93. Disc Medicine, Inc. has a 12-month low of $40.00 and a 12-month high of $99.50. The stock has a market cap of $2.71 billion, a price-to-earnings ratio of -10.72 and a beta of 0.93.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($1.65) earnings per share for the quarter, missing the consensus estimate of ($1.62) by ($0.03). On average, analysts expect that Disc Medicine, Inc. will post -6.74 EPS for the current year.

Institutional Investors Weigh In On Disc Medicine

Institutional investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. increased its holdings in Disc Medicine by 2.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,094 shares of the company’s stock worth $469,000 after buying an additional 138 shares in the last quarter. Arizona State Retirement System lifted its stake in Disc Medicine by 2.2% during the 4th quarter. Arizona State Retirement System now owns 6,798 shares of the company’s stock valued at $540,000 after acquiring an additional 144 shares during the period. Police & Firemen s Retirement System of New Jersey lifted its stake in Disc Medicine by 3.3% during the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 6,716 shares of the company’s stock valued at $533,000 after acquiring an additional 215 shares during the period. AlphaCentric Advisors LLC boosted its holdings in shares of Disc Medicine by 5.8% during the 1st quarter. AlphaCentric Advisors LLC now owns 3,972 shares of the company’s stock valued at $254,000 after acquiring an additional 216 shares during the last quarter. Finally, Avanza Fonder AB boosted its holdings in shares of Disc Medicine by 14.1% during the 4th quarter. Avanza Fonder AB now owns 1,903 shares of the company’s stock valued at $151,000 after acquiring an additional 235 shares during the last quarter. 83.70% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on IRON shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Disc Medicine in a research note on Monday, April 20th. Morgan Stanley upped their price target on shares of Disc Medicine from $80.00 to $85.00 and gave the stock an “overweight” rating in a research note on Monday. Truist Financial cut their price objective on shares of Disc Medicine from $114.00 to $83.00 and set a “buy” rating on the stock in a research report on Friday, February 27th. Wall Street Zen upgraded shares of Disc Medicine from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 25th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $88.00 target price on shares of Disc Medicine in a report on Wednesday, June 10th. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $105.80.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.